12-Dec-2024
No headlines found.
Health Catalyst to Participate in Upcoming Investor Conference
Globe Newswire (Tue, 10-Dec 8:05 AM ET)
Health Catalyst Launches AI-Enabled Cyber Protection Product for Healthcare
PRNewswire (Wed, 20-Nov 8:30 AM ET)
Health Catalyst to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 19-Nov 8:00 AM ET)
CyncHealth Selects Health Catalyst to Elevate Health Data Management
PRNewswire (Wed, 6-Nov 4:05 PM ET)
PRNewswire (Wed, 6-Nov 4:05 PM ET)
PRNewswire (Wed, 6-Nov 4:05 PM ET)
Health Catalyst Reports Third Quarter 2024 Results
Globe Newswire (Wed, 6-Nov 4:03 PM ET)
Globe Newswire (Wed, 23-Oct 8:00 AM ET)
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Health Catalyst trades on the NASDAQ stock market under the symbol HCAT.
As of December 12, 2024, HCAT stock price declined to $8.01 with 356,336 million shares trading.
HCAT has a beta of 1.59, meaning it tends to be more sensitive to market movements. HCAT has a correlation of 0.11 to the broad based SPY ETF.
HCAT has a market cap of $487.39 million. This is considered a Small Cap stock.
Last quarter Health Catalyst reported $76 million in Revenue and $.07 earnings per share. This beat revenue expectation by $53,000 and missed earnings estimates by -$.03.
In the last 3 years, HCAT traded as high as $41.28 and as low as $5.42.
The top ETF exchange traded funds that HCAT belongs to (by Net Assets): VTI, IWM, VXF, IWN, DFAT.
HCAT has underperformed the market in the last year with a price return of +9.9% while the SPY ETF gained +32.3%. HCAT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +0.8% and -7.4%, respectively, while the SPY returned +9.3% and +0.9%, respectively.
HCAT support price is $7.98 and resistance is $8.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCAT shares will trade within this expected range on the day.